Daiichi loses Supreme Court decision on Apotex generic

The U.S. Supreme Court dealt a blow to Daiichi Sankyo and Mylan ($MYL) when the court declined to hear their appeal in their attempt to head off drugmaker Apotex from introducing a generic version of the hypertension drug Benicar. The court let stand an earlier appellate court decision in favor of Apotex, which had reversed a previous decision by a federal court in Illinois that initially blocked Apotex. The lower court had dismissed the case before because Daiichi had "disclaimed the patent" in question, so it could not be infringed upon, according to a report from Reuters. Apotex had argued it needed a judgment of non-infringement to win approval from the U.S. Food and Drug Administration to begin selling a generic version, and the appeals court agreed, Reuters said. Report